Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.58 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.58 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.53 |
| ▸ | PIM1 | P11309 | 8/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 8/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17373838 | 1.00 | NTRK1 (0.58) | NTRK1MAP4K1FLT3PRKAA1IRAK4 | |
| SCHEMBL30659518 | 1.00 | NTRK1 (0.58) | NTRK1MAP4K1FLT3PRKAA1IRAK4 | |
| SCHEMBL22612503 | 0.93 | NTRK1 (0.52) | NTRK1MAP4K1FLT3PRKAA1IRAK4 | |
| SCHEMBL17373931 | 0.91 | IRAK4 (0.53) | NTRK1MAP4K1FLT3PRKAA1IRAK4 | |
| SCHEMBL17373928 | 0.91 | IRAK4 (0.53) | NTRK1MAP4K1FLT3PRKAA1IRAK4 | |
| SCHEMBL18391999 | 0.88 | IRAK4 (0.54) | NTRK1MAP4K1FLT3PRKAA1IRAK4 | |
| SCHEMBL16899254 | 0.85 | NTRK1 (0.53) | NTRK1MAP4K1FLT3PRKAA1IRAK4 | |
| SCHEMBL16899253 | 0.85 | NTRK1 (0.53) | NTRK1MAP4K1FLT3PRKAA1IRAK4 | |
| SCHEMBL17373857 | 0.85 | NTRK1 (0.52) | NTRK1MAP4K1FLT3PRKAA1IRAK4 | |
| SCHEMBL17373859 | 0.85 | NTRK1 (0.52) | NTRK1MAP4K1FLT3PRKAA1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704108-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Curis, Inc. (US) | 2020-09-09 | — | — | EP | claimed |
| CN-111225911-A | Compounds and compositions for treating hematological disorders | 库里斯公司 | 2020-06-02 | — | — | CN | claimed |
| EP-3600270-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Discovery Technologies Limited (IN) | 2020-02-05 | — | — | EP | claimed |
| CN-110691589-A | Compounds and compositions for treating hematological disorders | 奥列基因发现技术有限公司 | 2020-01-14 | — | — | CN | claimed |
| WO-2018178947-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-10-04 | — | — | WO | claimed |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-06-01 | — | — | US | claimed |
| EP-4410377-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Curis, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4252853-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Oncology Limited (IN) | 2023-10-04 | — | — | EP | disclosed |
| US-10758518-B2 | Compounds and compositions for treating hematological disorders | CURIS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190134010-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | CURIS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-06-01 | — | — | US | disclosed |
| EP-3157521-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015193846-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758518-B2 | Compounds and compositions for treating hematological disorders | IRAK4, IRAK2, JAK2 | NTRK1 3731/4885MAP4K1 472/4885FLT3 31/4885 |
| US-20190134010-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, IRAK2, JAK2 | NTRK1 3731/4885MAP4K1 472/4885FLT3 31/4885 |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK2 | NTRK1 2970/4885MAP4K1 192/4885FLT3 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.